Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 8 Saturday Friday Sunday Monday Tuesday Publication Only SATURDAY, JUNE 1 ST 1:15pm - 6:00pm Central Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 3:00 - 6:00pm 3:00 - 3:12pm Hall B1 Oral LBA1001 Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. Kalinsky K Hamilton E Breast Cancer - Metastatic 3:00 - 6:00pm 3:12 - 3:24pm Hall D1 Oral 3001 First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. Chandana S Garmezy B Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 3:00 - 6:00pm 4:00 - 4:12pm Arie Crown Theater Oral 5003 Health-related quality of life and pain in a phase 3 study of [177Lu] Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore). Fizazi K Fleming M Genitourinary Cancer— Prostate, Testicular, and Penile 3:00 - 6:00pm 4:12 - 4:24pm Hall D1 Oral 3005 First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations. Yap T Moore K Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 3:00 - 6:00pm 4:24 - 4:36pm Hall B1 Oral 1006 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2- negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. Pernas S Hamilton E Breast Cancer— Metastatic 3:00 - 6:00pm 4:24 - 4:36pm S100bc Oral LBA7005 Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. Kim JA Yasenchak C Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia 3:00 - 6:00pm 5:24 - 5:36pm Hall B1 Oral 1009 DESTINY-Breast07: Dose- expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. Andre F Hamilton E Breast Cancer— Metastatic 4:30 - 6:00pm 5:42 - 5:48pm S406 Oral 8521 Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated Phase 1 results (SGNB6A-001) Peters S Perez C, Fontana E Lung Cancer—Non- Small Cell Metastatic